| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H23N3O2 |
| Molecular Weight | 337.4155 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NC2=C(C=CC=C2)N1C3CCN(CCOC4=CC=CC=C4)CC3
InChI
InChIKey=NVDBBGBUTKLRSN-UHFFFAOYSA-N
InChI=1S/C20H23N3O2/c24-20-21-18-8-4-5-9-19(18)23(20)16-10-12-22(13-11-16)14-15-25-17-6-2-1-3-7-17/h1-9,16H,10-15H2,(H,21,24)
| Molecular Formula | C20H23N3O2 |
| Molecular Weight | 337.4155 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Oxiperomide was developed as a dopamine-receptor antagonist. Clinical trials have shown that this drug decreased dyskinesia in patients with Parkinson's disease receiving levodopa or other dopamine agonists without necessarily increasing Parkinsonian symptoms. However, information about the further development of this drug is not available.
